BR112017015431A2 - composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um composto - Google Patents

composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um composto

Info

Publication number
BR112017015431A2
BR112017015431A2 BR112017015431A BR112017015431A BR112017015431A2 BR 112017015431 A2 BR112017015431 A2 BR 112017015431A2 BR 112017015431 A BR112017015431 A BR 112017015431A BR 112017015431 A BR112017015431 A BR 112017015431A BR 112017015431 A2 BR112017015431 A2 BR 112017015431A2
Authority
BR
Brazil
Prior art keywords
treating
thrombus formation
compound
blood thrombus
methods
Prior art date
Application number
BR112017015431A
Other languages
English (en)
Inventor
Hruza Alan
Ali Amjad
Mertz Eric
L Brockunier Linda
MONINGKA Remond
F Neelamkavil Santhosh
D Edmondson Scott
So Sung-Sau
Sun Wanying
Liu Weiguo
Gao Ying-Duo
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112017015431A2 publication Critical patent/BR112017015431A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção provê um composto de fórmula i i e composições farmacêuticas, compreendendo um ou mais dos ditos compostos, e métodos para usar os ditos compostos para tratar ou prevenir a trombose, embolias, hipercoagulabilidade ou alterações fibróticas. os compostos são inibidores seletivos do fator xia ou inibidores duplos do fator xia e da calicreína plasmática.
BR112017015431A 2015-01-20 2016-01-15 composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um composto BR112017015431A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105385P 2015-01-20 2015-01-20
PCT/US2016/013507 WO2016118403A1 (en) 2015-01-20 2016-01-15 Factor xia inhibitors

Publications (1)

Publication Number Publication Date
BR112017015431A2 true BR112017015431A2 (pt) 2018-01-16

Family

ID=56417605

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015431A BR112017015431A2 (pt) 2015-01-20 2016-01-15 composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um composto

Country Status (11)

Country Link
US (1) US10123995B2 (pt)
EP (1) EP3247354B1 (pt)
JP (1) JP2018502137A (pt)
KR (1) KR20170103962A (pt)
CN (1) CN107106548A (pt)
AU (1) AU2016209623B2 (pt)
BR (1) BR112017015431A2 (pt)
CA (1) CA2973202A1 (pt)
MX (1) MX2017009445A (pt)
RU (1) RU2712268C2 (pt)
WO (1) WO2016118403A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016018702A1 (en) * 2014-07-28 2016-02-04 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
EP3283464B1 (en) * 2015-04-16 2019-10-23 Merck Sharp & Dohme Corp. Factor xia inhibitors
US10472344B2 (en) 2015-12-02 2019-11-12 Merck Sharp & Dohme Corp. Factor XIa inhibitors
TW201808908A (zh) 2016-08-22 2018-03-16 美商默沙東藥廠 因子XIa抑制劑
EP3351122B1 (en) * 2016-10-12 2020-06-17 Changzhou Patent Electronic Technology Co., Ltd Mouth piece of electronic cigarette, e-liquid cartridge, and electronic cigarette
WO2021121396A1 (zh) * 2019-12-20 2021-06-24 成都康弘药业集团股份有限公司 作为血浆激肽释放酶抑制剂的三环类化合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163749B2 (en) * 2005-12-14 2012-04-24 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7829584B2 (en) * 2006-03-21 2010-11-09 Janssen Pharmaceutica Nv Pyridines and pyridine N-oxides as modulators of thrombin
TW200848024A (en) * 2007-06-13 2008-12-16 Bristol Myers Squibb Co Dipeptide analogs as coagulation factor inhibitors
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
AU2011215898B2 (en) * 2010-02-11 2016-08-11 Bristol-Myers Squibb Company Macrocycles as Factor XIa inhibitors
US8592426B2 (en) * 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
WO2013028474A1 (en) 2011-08-19 2013-02-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
KR20150047609A (ko) * 2012-08-30 2015-05-04 니뽄 신야쿠 가부시키가이샤 피리딘 유도체 및 의약
EP2922535B1 (en) * 2012-11-20 2021-11-10 Merck Sharp & Dohme Corp. Thrombin inhibitors
CN106413710A (zh) 2014-05-28 2017-02-15 默沙东公司 因子XIa抑制剂
WO2016018701A1 (en) 2014-07-28 2016-02-04 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2016018702A1 (en) 2014-07-28 2016-02-04 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
EP3180317B1 (en) 2014-07-28 2021-04-14 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS

Also Published As

Publication number Publication date
RU2017129275A (ru) 2019-02-21
EP3247354A4 (en) 2018-06-27
MX2017009445A (es) 2017-11-08
US20180000795A1 (en) 2018-01-04
EP3247354B1 (en) 2019-08-07
RU2017129275A3 (pt) 2019-07-26
CA2973202A1 (en) 2016-07-28
RU2712268C2 (ru) 2020-01-28
KR20170103962A (ko) 2017-09-13
WO2016118403A1 (en) 2016-07-28
CN107106548A (zh) 2017-08-29
EP3247354A1 (en) 2017-11-29
AU2016209623A1 (en) 2017-07-13
JP2018502137A (ja) 2018-01-25
US10123995B2 (en) 2018-11-13
AU2016209623B2 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
BR112017015431A2 (pt) composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um composto
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
EA033395B1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
BR112018008506B8 (pt) Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
TN2017000009A1 (en) Spirocycloheptanes as inhibitors of rock.
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
EA201692487A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2017011000A (es) Compuestos de pirazol sustituidos como inhibidores de serina proteasa.
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201791451A1 (ru) 5-[(пиперазин-1-ил)-3-оксо-пропил]-имидазолидин-2,4-дионовые производные в качестве ингибиторов adamts для лечения остеоартрита
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
EA201990095A1 (ru) КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements